Last reviewed · How we verify

ketamine + clonidine — Competitive Intelligence Brief

ketamine + clonidine (ketamine + clonidine) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Area: Pain management.

phase 3 NMDA receptor, alpha-2 adrenergic receptor Pain management Small molecule Live · refreshed every 30 min

Target snapshot

ketamine + clonidine (ketamine + clonidine) — Irmandade da Santa Casa de Misericordia de Sao Paulo. Ketamine acts as an NMDA receptor antagonist, while clonidine is an alpha-2 adrenergic receptor agonist.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ketamine + clonidine TARGET ketamine + clonidine Irmandade da Santa Casa de Misericordia de Sao Paulo phase 3 NMDA receptor, alpha-2 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape

No sponsor landscape data.

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ketamine + clonidine — Competitive Intelligence Brief. https://druglandscape.com/ci/ketamine-clonidine. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: